NT5E and posterior cortical atrophy: Other immune checkpoints are gaining more interest as potential targets in recent years, including the adenosinergic CD73-axis 75, 129 and the non-classical Human leukocyte antigen (HLA)-G 119, 130, 131, both of which are being investigated in clinical trials for PCa (see Table 1).